Log in

Relevant bibliographies by topics / Antihistamine

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'Antihistamine'

Author: Grafiati

Published: 4 June 2021

Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Antihistamine.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Antihistamine"

1

Maeda, Toshiki, Akira Babazono, and Takumi Nishi. "Surveillance of First-Generation H1-Antihistamine Use for Older Patients with Dementia in Japan: A Retrospective Cohort Study." Current Gerontology and Geriatrics Research 2018 (July 2, 2018): 1–6. http://dx.doi.org/10.1155/2018/3406210.

Full text

Abstract:

Background. This study aimed to investigate the rate of first-generation H1-antihistamines use for older adults with dementia in Japan. Methods. The study design was retrospective cohort using claims data between fiscal years 2010 and 2013. Subjects were 75 years or older, diagnosed with dementia, and given H1-antihistamines orally during the study period after being diagnosed with dementia. We investigated the cumulative number of oral H1-antihistamines administered and the relationship between first-generation H1-antihistamine use and each explanatory variable using crude and adjusted odds ratio. Results. The cumulative total for use of first-generation H1-antihistamine for older adults with dementia accounted for 32.1% of all antihistamine medication. The majority of first-generation H1-antihistamine prescriptions were indicated for cold treatment. Those with upper respiratory infection or asthma had a significantly positive relationship with first-generation H1-antihistamine use. Conclusion. The study showed that first-generation H1-antihistamine drugs were highly prescribed in older adults with dementia in Japan.

APA, Harvard, Vancouver, ISO, and other styles

2

Daida, Atsuro, Gaku Yamanaka, Shin-ichi Tsujimoto, Mina Yokoyama, Kuniyoshi Hayashi, Kevin Y. Urayama, Yasushi Ishida, et al. "Relationship between Sedative Antihistamines and the Duration of Febrile Seizures." Neuropediatrics 51, no. 02 (January 14, 2020): 154–59. http://dx.doi.org/10.1055/s-0040-1701226.

Full text

Abstract:

AbstractSome studies have shown that sedative antihistamines prolong febrile seizure duration. Although the collective evidence is still mixed, the Japanese Society of Child Neurology released guidelines in 2015 that contraindicated the use of sedative antihistamines in patients with febrile seizure. Focused on addressing limitations of previous studies, we conducted a cross-sectional study to evaluate the relationship between febrile seizure duration and the use of sedative antihistamines. Data were collected from patients who visited St. Luke's International Hospital due to febrile seizure between August 2013 and February 2016. Patients were divided into groups based on their prescribed medications: sedative antihistamine, nonsedative antihistamine, and no antihistamine. Seizure duration was the primary outcome and was examined using multivariate analyses. Of the 426 patients included, sedative antihistamines were administered to 24 patients. The median seizure duration was approximately 3 minutes in all three groups. There was no statistical difference in the bivariate (p = 0.422) or multivariate analyses (p = 0.544). Our results do not support the relationship between sedative antihistamine use and prolonged duration of febrile seizure. These results suggest that the use of antihistamines may be considered for patients with past history of febrile seizure, when appropriate.

APA, Harvard, Vancouver, ISO, and other styles

3

Kawano, T., B. E. Grunau, K. Gibo, F. X. Scheuermeyer, and R. Stenstrom. "LO066: H1-antihistamine administration is associated with a lower likelihood of progression to anaphylaxis among emergency department patients with allergic reactions." CJEM 18, S1 (May 2016): S53. http://dx.doi.org/10.1017/cem.2016.103.

Full text

Abstract:

Introduction: H1-antihistamines are often used to treat allergic reactions, however, the influence of H1-antihistamines on progression to anaphylaxis remains unclear. Among patients initially presenting with allergic reactions, we investigated whether H1-antihistamines were associated with a lower proportion of patients progressing to anaphylaxis during observation. Methods: This was a retrospective cohort study conducted at two urban EDs from 2007 to 2012. We included adult patients with allergy and excluded those who met criteria of anaphylaxis at first evaluation by medical professionals and/or received antihistamines before the evaluation. Primary outcomes of interest were the number of patients who developed anaphylaxis during observation at ED and/or transportation by EMS. Secondary outcomes were the number of biphasic reactions and severe anaphylaxis (defined as sBP<90; SpO2<92%; and/or confusion, collapse, loss of conscious, or incontinence). Logistic regression was performed comparing primary and secondary outcomes between H1-antihistamine treated and non-treated groups with propensity score adjustment of the baseline covariates. Number needed to treat (NNT) was calculated by adjusted absolute risk reduction of H1-antihistamine compared to non H1-antihistamine use on primary outcome. Results: This study included 1717 patients with allergic reactions, of whom 1228 were treated with H1-antihistamines. In the H1-antihistamine group 1.0% and 0.2% developed anaphylaxis and severe anaphylaxis, respectively; in the non-H1-antihistamine group 2.6% and 0.6% developed anaphylaxis and severe anaphylaxis, respectively. There were no biphasic reactions (0%, 95% confidence interval [CI] 0 to 0.17%). Administration of H1-antihistamines was associated with a lower incidence of subsequent anaphylaxis (adjusted odds ratio [OR] 0.23, 95% CI 0.10 to 0.53; NNT to benefit 49.1, 95% CI 41.6 to 83.3). There were no significant associations between H1-histamines administration and secondary outcomes. Conclusion: Among ED patient with allergic reactions, H1-antihistamine administration was associated with a lower likelihood of progression to anaphylaxis. These findings suggest that H1-antihistamines should be administered early in the care of patients with allergic reactions.

APA, Harvard, Vancouver, ISO, and other styles

4

Rabari, Haribhai, Beenkumar Prajapati, and Preeti Rajput. "Synthesis and Screening of Some Novel Thieno[2,3-d][1,2,3] triazine Derivatives as Non-sedative H1 Antihistaminics." International Journal of Pharmaceutical Sciences and Nanotechnology 13, no. 4 (July 12, 2020): 5000–5004. http://dx.doi.org/10.37285/ijpsn.2020.13.4.5.

Full text

Abstract:

Histamine receptor H1 antagonists are widely used as antihistamines for allergy conditions. The brain-penetrating antihistamines can cause sedation and some with poor-penetration do not cause sedation potential. In the present study, a new series of thieno[2,3-d][1,2,3]triazine derivatives 7a-e have been synthesized and screened for their H1 antihistaminic activity and sedation potential. Among all the screened compounds, compound 7b, 7c and 7d, show high H1 antihistaminic activity with IC50 value of 0.1 - 0.8 µM, which are comparable with that of the standard drug cetirizine. The sedative potential of the compounds was tested on albino mice using the photoactometer method. All the three compounds show less sedation potential than that of the standard drug diphenhydramine. In conclusion, the novel compounds appear with promising potential as non-sedating antihistamine agents.

APA, Harvard, Vancouver, ISO, and other styles

5

Oyekan, P. J., H. C. Gorton, and C. S. Copeland. "Over-the-counter antihistamines in drug-related deaths: a population-based case series." International Journal of Pharmacy Practice 29, Supplement_1 (March 26, 2021): i30—i31. http://dx.doi.org/10.1093/ijpp/riab015.037.

Full text

Abstract:

Abstract Introduction Antihistamines are not one of the medicine groups reported on in the Office for National Statistics drug-related death data. (1) However, there is concern that first-generation antihistamines are misused for their sedative properties. This is amplified by a recent social media challenge, which resulted in deaths due to diphenhydramine overdose. (2) The extent of the involvement of antihistamines in deaths is largely unknown. Aim We aimed to evaluate deaths related to antihistamines in England (2000–2019) by individual drug, medicine classification (POM, P, GSL), whether the drug was considered attributable to the death (known as implication rate), or incidental; and examine temporal trends. Methods Deaths are reported voluntarily by coroners to the National Programme on Substance Abuse Deaths (NPSAD) in cases where psychoactive drugs were detected at post-mortem and/or when the decedent was known to abuse drugs. NPSAD holds data on decedent demographics (gender, age, employment status, living arrangements), details pertaining to the death (cause(s) of death, manner of death, conclusion of inquest, toxicology reports) and past social and medical histories, including drugs prescribed. From this dataset, we extracted all cases where an antihistamine was detected at post-mortem between 2000 and 2019. We report descriptive statistics to describe the reporting of antihistamines in deaths. Results We identified 1666 antihistamine detections from 1537 individuals. The significant majority of these were sedative antihistamines which are classed as pharmacy medicines (P) (85.2%, p<0.01); deaths where prescription-only antihistamines were detected represented fewer than 7.0% of cases. Despite an increasing trend for antihistamine detections in deaths over time, the proportion of deaths where the detected antihistamine was implicated in causing the death declined over the same period (average implication rate 2000–2005: 58.7%; 2014–2019: 28.4%). Whilst death was deemed accidental in the majority of cases (66.1%), a significant proportion of cases were concluded as suicide (20.9%, p<0.01).Polydrug use was evident in the vast majority of cases (98.5%), with central nervous system depressants the most commonly co-administered substances (94.8% of cases). Conclusion We describe the first report regarding antihistamine-related mortality from England. From the NPSAD, we can obtain prescription source and toxicology reports, beyond those reported in national death data. Although incomplete, the response from coroners is good (89%), and provides sufficient cause for concern. The rising trend in antihistamine-related deaths may in-part be contributed to by the perceived negligible dangers associated with antihistamines, both from the general public and professionals. Awareness of the dangerous sedative properties that some antihistamines possess is however heightened in individuals who are deliberately seeking out these effects. An urgent review of sedating antihistamines currently assigned under the P classification is needed to achieve antihistamine harm reduction, balanced against the self-care they enable. References 1. Office for National Statistics. Deaths related to drug poisoning in England and Wales: 2019 registration [internet]. 2020 [cited 18 Oct 2020]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsrelatedtodrugpoisoninginenglandandwales/2019registrations 2. US FDA. Benadryl (diphenhydramine): Drug Safety Communication - Serious Problems with High Doses of the Allergy Medicine. 2020.

APA, Harvard, Vancouver, ISO, and other styles

6

Yehya, Alaa, Mohammad Numan, and Laila Matalqah. "No Time for Lullabies: Tracing down Pharmacological Effects & Uses of H1-Antihistamines in Children Younger than 6 Years." Global Pediatric Health 8 (January 2021): 2333794X2199217. http://dx.doi.org/10.1177/2333794x21992170.

Full text

Abstract:

Objectives. To provide a qualitative and a quantitative analysis of H1-antihistamines pharmacological uses pattern among children (<6 years old) and to evaluate the parental-related awareness. Methods. A cross-sectional study was carried out at 5 retail pharmacies in Jordan over 5 months (October/2019-February/2020). Parents who requested any of H1-antihistmine agent for a child (<6 years) were invited to participate. Results. A total of 516 children, most of them were toddlers (1-3) years, received at least 1 H1-antihistamine. More than half of the cases received H1-antihistamine as self-medication (56.3%). Sedating antihistamine agents were the most frequently used among children (<6 years old) (77.9%) among which Chlorpheniramine maleate was the most commonly used agent (62.9%). About half of the children (47.0%) received H1-antihistamine to induce sleep. Whereas, 21.7% and 12.9% received them to manage flu, and allergic rhinitis (AR), respectively. Around 66.6% of the cases were classified as off-label use. Most of the parents (80.5%) were aware of the sedative adverse effects of H1-antihistamines, whereas a fewer number (31.9%) were aware of their cognitive effects. Finally, more than two thirds of parents (79.7%) were unfamiliar with off-label drug use in children. Conclusion. Despite the availability of less-sedating H1-antihistamines with a wide safety and efficacy record, the use of sedating H1-antihistamines remains popular in children.

APA, Harvard, Vancouver, ISO, and other styles

7

Wong-Sefidan, Ida, and Eric Roeland. "Re-evaluating the inpatient use of routine diphenhydramine transfusion premedication practices." Journal of Clinical Oncology 31, no. 31_suppl (November 1, 2013): 164. http://dx.doi.org/10.1200/jco.2013.31.31_suppl.164.

Full text

Abstract:

164 Background: Routine diphenhydramine premedication to prevent allergic transfusion reactions is common practice despite lack of evidence. First-generation antihistamines are associated with a number of anticholinergic side effects such as sedation and cognitive impairment that impact patient care and increase cost. Because premedication should be evidence-based and patient-specific, the University of California, San Diego (UCSD) inpatient Bone Marrow Transplant (BMT) service implemented a transfusion premedication protocol, specifically addressing antihistamine use. Methods: To revise the protocol, a committee was formed. The committee reviewed evidence-based practices, challenges, pharmacology, and costs of antihistamines, and developed an inpatient BMT antihistamine premedication protocol that omitted pre-ordered diphenhydramine and offered cetirizine as a first-choice premedication. Antihistamine premedication was encouraged for high risk patients only. A retrospective comparison of antihistamine prophylaxis pre (2010-2011) and post (2011-2012) protocol implementation was completed. The number of antihistamine doses and transfusions was computed by a count from the electronic medical records. Results: Despite a 14% increase in transfusions, the number of BMT inpatient antihistamine premedication orders decreased by 26%. Diphenhydramine use decreased from 85.9% to 34.2%, while cetirizine use increased from 3.3% to 55.9%. Conclusions: The evidence-based, risk-stratified antihistamine premedication protocol decreased the use of diphenhydramine. Limitations include the retrospective design and lack of data comparing reactions in patients who did and did not receive premedication. Our institution plans to expand this study and complete a prospective evaluation of safely and rationally administered transfusion premedication with the goal to evaluate premedication-related toxicity and methods to improve the quality of life in our patients. [Table: see text]

APA, Harvard, Vancouver, ISO, and other styles

8

Silverman, H. J., W. R. Taylor, P. L. Smith, A. Kagey-Sobotka, S. Permutt, L. M. Lichtenstein, and E. R. Bleecker. "Effects of antihistamines on the cardiopulmonary changes due to canine anaphylaxis." Journal of Applied Physiology 64, no. 1 (January 1, 1988): 210–17. http://dx.doi.org/10.1152/jappl.1988.64.1.210.

Full text

Abstract:

Histamine has long been considered to be an important chemical mediator in the pathogenesis of immediate hypersensitivity reactions. We evaluated the efficacy of antihistamines to determine the physiological role of histamine in canine anaphylaxis. Either a saline vehicle (control group), an H1 antihistamine (chlorpheniramine, 10 mg/kg), or this H1 antihistamine and an H2 antihistamine (cimetidine, 30 mg/kg) was administered to three separate groups of anesthetized dogs (n = 8). Cardiopulmonary responses and plasma histamine levels were measured after the separate intravenous injection of Ascaris suum antigen and histamine. Results were analyzed only from the animals demonstrating physiological responses or histamine release after antigen injection. In the control group, antigen produced a 43 +/- 15% (mean +/- SE) decrease in mean arterial blood pressure, a 34 +/- 13% fall in cardiac output, and a 19 +/- 9% decrease in lung compliance, whereas pulmonary vascular resistance increased 161 +/- 87% and airway resistance rose 114 +/- 66%. Similar physiological abnormalities were observed with histamine shock. However, peak plasma histamine levels were, in most cases, greater after histamine injection than after antigen injection. An H1 antihistamine alone or in combination with an H2 antihistamine did not alter the physiological changes associated with systemic anaphylaxis. In contrast, the combined use of H1 and H2 antihistamines prevented the cardiopulmonary responses associated with the intravenous administration of histamine.(ABSTRACT TRUNCATED AT 250 WORDS)

APA, Harvard, Vancouver, ISO, and other styles

9

Connell, John T., J. Campbell Howard, William Dressier, and James L. Perhach. "Antihistamines: Findings in Clinical Trials Relevant to Therapeutics." American Journal of Rhinology 1, no. 1 (March 1987): 3–16. http://dx.doi.org/10.2500/105065887781390363.

Full text

Abstract:

Antihistamine therapy reduces hay fever symptoms 50–60% within 5 hours after the first dose. Treatment for 9 days maintains but does not reduce symptoms further. Patients treated with placebo for 8 days and then treated with chlorpheniramine obtained as much relief by the 5th hour after treatment as those treated with chlorpheniramine for 9 days. Increasing the dose of any antihistamine we tested over that necessary for maximal relief produces no greater benefit. Antihistamine treatment doses currently recommended may be greater than necessary for most patients. Antihistamines do not reduce nasal congestion and are not decongestants.

APA, Harvard, Vancouver, ISO, and other styles

10

Lee Barnes, Connie, Constance A. McKenzie, Kathy D. Webster, and Kim Poinsett-Holmes. "Cetirizine: A New, Nonsedating Antihistamine." Annals of Pharmacotherapy 27, no. 4 (April 1993): 464–70. http://dx.doi.org/10.1177/106002809302700414.

Full text

Abstract:

OBJECTIVE: To introduce cetirizine, a nonsedating antihistamine, and discuss its mechanism of action, chemistry, clinical and comparative trials, and adverse effects. DATA SOURCES: An English-language literature search of MEDLINE was conducted. STUDY SELECTION: Human clinical trials were selected for evaluation. DATA SYNTHESIS: Cetirizine, an investigational agent and a potent histamine1-antagonist is a piperazine derivative and carboxylated metabolite of hydroxyzine. As a second-generation, nonsedating antihistamine, cetirizine is associated with fewer adverse effects compared with first-generation antihistamines. It appears to be at least as effective as the other nonsedating antihistamines in the treatment of allergic rhinitis, chronic idiopathic urticaria, and pollen-induced asthma. The recommended adult dosage of this agent is 5 or 10 mg/d. CONCLUSIONS: Clinical studies indicate that cetirizine may be more beneficial in some ways than other available agents. Two of these advantages are a rapid onset of action and a once-daily dosing regimen. Future postmarketing surveillance is warranted to further document these findings.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Antihistamine"

1

Rice, Valerie J. Berg. "Complex cognitive performance and antihistamine use." Diss., This resource online, 1990. http://scholar.lib.vt.edu/theses/available/etd-02052007-081232/.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Delargy, Paula M. C. "Quantifying adverse reactions to antihistamine compounds." Thesis, Queen's University Belfast, 1993. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.359062.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Baxter, R. I. "Voltammetric studies of some important antihistamine drugs." Thesis, Queen's University Belfast, 1985. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.374204.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Whitehouse, Gail Lynn. "The effects of antihistamine use on visual search tasks." Thesis, Virginia Tech, 1990. http://hdl.handle.net/10919/41500.

Full text

Abstract:

Previous research has shown that most antihistamines have sedative effects and can lead to deterioration of psychomotor performance. The objective of this research was to determine if two antihistamines (diphenhydramine and astemizole) administered at a therapeutic dose level will affect a subject's visual search capabilities. The results of this research indicate that astemizole did not significantly decrement a subject’s ability to visually search as compared to the performance of that same subject after ingesting a placebo. Diphenhydramine produced significantly poorer visual search results than did astemizole.
Master of Science

APA, Harvard, Vancouver, ISO, and other styles

5

Treherne, Jonathan Mark. "A quarternary radioligand for histamine Hâ†1-receptor." Thesis, University of Cambridge, 1987. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.328973.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Donado, Budiño Esther Guillermina. "Evaluation of caridotoxicity of rupatadine, and antihistamine, as recommendeded by ICH E14." Doctoral thesis, Universitat Autònoma de Barcelona, 2016. http://hdl.handle.net/10803/370122.

Full text

Abstract:

OBJETIVOS: Para evaluar los efectos de las dosis terapéuticas y supraterapéuticas de rupatadina en la repolarización cardiaca mediante un 'thorough QT/QTc study', realizado de acuerdo con la Conferencia Internacional sobre las directrices de armonización. MÉTODOS: Ensayo clínico, de grupos paralelos (balanceado por género), aleatorio, que incluyó 160 voluntarios sanos. Tanto rupatadina, 10 y 100 mg od, como placebo, se administraron durante 5 días en simple ciego, mientras que moxifloxacino 400 mg/día, se administró los días 1 y 5 en abierto. Los registros ECG se recogieron durante un período de 23 h mediante Holter en el día basal del estudio y durante el tratamiento en los días 1 y 5. Se descargaron tres muestras de 10-s ECG a intervalos regulares y se analizaron de forma independiente. El análisis primario de QTc se basó en QT corregido de forma individual (QTcI). Los efectos del tratamiento sobre QTcI se evaluaron utilizando la mayor diferencia de medias vez emparejados entre el medicamento y el placebo (baseline-subtracted) para el intervalo QTcI. Un "thorough QT/QTc study" negativo es aquel en el que la variable principal es de alrededor de < o = 5 ms, con un intervalo de confianza unilateral del 95% que excluye un efecto > 10 ms. RESULTADOS: La validez de la prueba fue confirmada por el hecho de que el grupo de control positivo-moxifloxacino- produjo el cambio esperado en la duración QTci (alrededor de 5 ms). Los datos del ECG con rupatadina a dosis 10 y 100 mg no mostraron efectos relevantes en el ECG, ni después de la administración única ni tras administración repetida. Además, no se observó ninguna relación farmacocinética / farmacodinámica, efectos de género o cambios clínicamente relevantes en los valores extremos o de morfología en el ECG. No se reportaron muertes ni eventos adversos graves o inesperadas. CONCLUSIONES: Este "'thorough QT/QTc study' 'confirmó la experiencia previa con rupatadina y demostró que no presenta potencial proarrítmico y no planteó preocupaciones con respecto a su seguridad cardíaca.
AIMS: To evaluate the effects of therapeutic and supratherapeutic doses of rupatadine on cardiac repolarization in line with a 'thorough QT/QTc study' protocol performed according to International Conference on Harmonization guidelines. METHODS: This was a randomized (gender-balanced), parallel-group study involving 160 healthy volunteers. Rupatadine, 10 and 100 mg od, and placebo were administered single-blind for 5 days, whilst moxifloxacin 400 mg/day was given on days 1 and 5 in open-label fashion. ECGs were recorded over a 23-h period by continuous Holter monitoring at baseline and on treatment days 1 and 5. Three 10-s ECG samples were downloaded at regular intervals and were analysed independently. The primary analysis of QTc was based on individually corrected QT (QTcI). Treatment effects on QTcI were assessed using the largest time-matched mean difference between the drug and placebo (baseline-subtracted) for the QTcI interval. A negative 'thorough QT/QTc study' is one where the main variable is around < or =5 ms, with a one-sided 95% confidence interval that excludes an effect >10 ms. RESULTS: The validity of the trial was confirmed by the fact that the moxifloxacinpositive control group produced the expected change in QTcI duration (around 5 ms). The ECG data for rupatadine at both 10 and 100 mg showed no signal effects on the ECG, after neither single nor repeated administration. Furthermore, no pharmacokinetic/pharmacodynamic relationship, gender effects or clinically relevant changes in ECG waveform outliers were observed. No deaths or serious or unexpected adverse events were reported. CONCLUSIONS: This 'thorough QT/QTc study' confirmed previous experience with rupatadine and demonstrated that it had no proarrhythmic potential and raised no concerns regarding its cardiac safety.

APA, Harvard, Vancouver, ISO, and other styles

7

Lindmark, Elin. "Dykare i Difenhydramin : Förändrar antihistaminet difenhydramin beteendet hos dykarlarver, Dytiscidae?" Thesis, Umeå universitet, Institutionen för ekologi, miljö och geovetenskap, 2019. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-159825.

Full text

Abstract:

A diverse cocktail of pharmaceuticals is spreading via water treatment plants’ effluent to surface water with known and unknown consequences of individual organisms and the ecosystem. In prior research on what consequences the pharmaceutical discharge can have, the antihistamine diphenhydramine has been found in surface waters and has been linked to alteration in organisms’ behaviours. In this study, Dytiscidae larvae were filmed before and after being exposed to diphenhydramin with a concentration of 1 µg/l. The exposure was done using four different treatments: no diphenhydramine, diphenhydramine in water, in their food or in both water and food. This was done to observe whether the behaviour, specifically activity and boldness, of Dytiscidae larvae would change with the exposure of the antihistamine and therefore potentially be a problem in aquatic ecosystems exposed to effluent. The experiment showed a significant difference (P = 0.015) between larvae in the control group and larvae only exposed to diphenhydramine through water, where exposed larvae were less active than the control group. Also, a trend pointed to a potential difference in exploration between the same groups, where the group exposed to diphenhydramine explored more than the control group. No behavioural change was found when larvae was exposed via food or food and water. The changed behaviour found here could influence fitness of the larvae and potentially also other parts of the ecosystem through cascading effects. Further research is required to confirm the dangers and consequences of diphenhydramine in surface waters, but my results suggest that it can alter the organism’s behaviour in aquatic ecosystems.

APA, Harvard, Vancouver, ISO, and other styles

8

Koch, Katja [Verfasser]. "Antihistamine updosing reduces disease activity in difficult-to-treat cholinergic urticaria patients / Katja Koch." Berlin : Medizinische Fakultät Charité - Universitätsmedizin Berlin, 2017. http://d-nb.info/1127579959/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Schooley, Elizabeth K. "The effects of an antiseritonergic drug and antihistamine in an experimental model of feline asthma." Diss., Columbia, Mo. : University of Missouri-Columbia, 2007. http://hdl.handle.net/10355/5033.

Full text

Abstract:

Thesis (M.S.)--University of Missouri-Columbia, 2007.
The entire dissertation/thesis text is included in the research.pdf file; the official abstract appears in the short.pdf file (which also appears in the research.pdf); a non-technical general description, or public abstract, appears in the public.pdf file. Vita. "May 2007" Includes bibliographical references.

APA, Harvard, Vancouver, ISO, and other styles

10

Verner, Jennifer Joan. "Formulation and dissolution assessment of a novel repeat action tablet containing a decongestant and an antihistamine." Thesis, Rhodes University, 2001. http://hdl.handle.net/10962/d1003276.

Full text

Abstract:

Controlled and sustained release dosage forms are the focus of worldwide research. These dosage forms facilitate patient compliance by simplifying the dosage regimen, and decrease the risk of adverse effects by reducing large fluctuations in the plasma concentration of the drug. The objective of this study was to formulate a repeat-action tablet to provide a sustained release dose of pseudoephedrine sulfate (PSS), and an immediate release dose of both PSS and loratadine. The release profile was compared to that of a commercially available preparation, Clarityne-D®. This formulation developed presents a novel mechanism of sustaining the release of PSS. The prototype tablet consisted of a sustained release core coated with an ethylcellulose dispersion to introduce a lag phase into the release profile and a second outer film coat incorporating PSS and loratadine. The core comprised an ethylcellulose granulation of PSS compressed into a hydroxypropyl methylcellulose matrix. The release of PSS from prototypes was assessed using USP Apparatus 3, as this apparatus was more representative of in vivo conditions and discriminated more effectively between the different tablet compositions produced during development. All dissolution samples were analysed for PSS and loratadine using validated highperformance liquid chromatographic methods. The prototype sustained release cores were found to be more resistant than the reference product to elevated temperature and humidity (40°C/87% RH) with fewer observed changes to the release profiles following storage for up to six months. This study was a feasibility study to obtain proof of concept. The release profile obtained from the prototype tablets was similar (f₂ = 50.0) to that of the reference product. Further development and optimisation of this dosage form is necessary, including evaluation of the choice of hydrophobic polymer, the effect of compression force and tablet geometry and characterisation of the release mechanism from the coated matrix. Assessment of these factors is necessary in order to optimise the formulation with respect to the desired therapeutic objectives.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Antihistamine"

1

name, No. Histamine and H1-antihistamines in allergic disease. 2nd ed. New York, NY: Marcel Dekker, 2003.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

The allergic reaction. 2nd ed. Braine-L'Alleud: UCB Pharmaceutical Sector, 1993.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Melnick, R. NTP technical report on the toxicology and carcinogenesis studies of Diphenhydramine hydrochloride (CAS no. 147-24-0) in F344/N rats and B6C3F1 mice (feed studies). Research Triangle Park, NC: National Toxicology Program, U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Seto, Arnold Henning. Meta-analysis of adverse neonatal effects due to maternal exposure to antihistamines. Ottawa: National Library of Canada, 1994.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Zemskov, Vladimir, and Veronika Zemskova. Immunotropic effects of therapeutic factors. ru: INFRA-M Academic Publishing LLC., 2020. http://dx.doi.org/10.12737/1039485.

Full text

Abstract:

Data on the immunotropic effects of traditional drugs - antibiotics, antihistamines, anti-inflammatory, and metabolic agents-are summarized. The profile properties of cytostatics, immune globulins, cytokines, vaccines, interferons and their ability to develop General organizational effects are analyzed. Data on the types, blocks, principles of immunotherapy administration, and ways to prevent complications are highlighted. For students and teachers, as well as employees of medical universities.

APA, Harvard, Vancouver, ISO, and other styles

6

(Canada), Expert Advisory Committee on Nonprescription Cough and Cold Remedies. First report. Ottawa: National Health and Welfare Canada, 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Parker, James N., and Philip M. Parker. Claritin: A medical dictionary, bibliography, and annotated research guide to Internet references. San Diego, CA: ICON Health Publications, 2003.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Parker, Philip M., and James N. Parker. Benadryl: A medical dictionary, bibliography, and annotated research guide to Internet references. San Diego, CA: ICON Health Publications, 2003.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Parker, Philip M., and James N. Parker. Claritin-D: A medical dictionary, bibliography, and annotated research guide to Internet references. San Diego, CA: ICON Health Publications, 2004.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Parker, James N., and Philip M. Parker. Promethazine: A medical dictionary, bibliography, and annotated research guide to Internet references. San Diego, CA: ICON Health Publications, 2004.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Antihistamine"

1

Gooch, Jan W. "Antihistamine." In Encyclopedic Dictionary of Polymers, 874. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-1-4419-6247-8_13149.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Johnston, Carol S. "The Antihistamine Action of Ascorbic Acid." In Subcellular Biochemistry, 189–213. Boston, MA: Springer US, 1996. http://dx.doi.org/10.1007/978-1-4613-0325-1_10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Källén, Bengt. "Maternal Use of Antihistamine Drugs for Allergy and Infant Congenital Malformations." In Maternal Drug Use and Infant Congenital Malformations, 383–88. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-17898-7_34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Gaudy-Marqueste, Caroline. "Antihistamines." In Pruritus, 276–88. London: Springer London, 2009. http://dx.doi.org/10.1007/978-1-84882-322-8_44.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Lieberman, Phil. "Antihistamines." In Allergic Diseases, 323–35. Totowa, NJ: Humana Press, 2000. http://dx.doi.org/10.1007/978-1-59259-007-0_17.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

D’Erme, Angelo Massimiliano, Serena Gianfaldoni, Andreas D. Katsambas, and Torello M. Lotti. "Antihistamines." In European Handbook of Dermatological Treatments, 1373–80. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-662-45139-7_133.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Scherrmann, Jean-Michel, Kim Wolff, Christine A. Franco, Marc N. Potenza, Tayfun Uzbay, Lisiane Bizarro, David C. S. Roberts, et al. "Antihistamines." In Encyclopedia of Psychopharmacology, 108. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-540-68706-1_3059.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Balamane, Maya, and Stephanie A. Kolakowsky-Hayner. "Antihistamines." In Encyclopedia of Clinical Neuropsychology, 283–84. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-57111-9_1628.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Gaudy-Marqueste, Caroline. "Antihistamines." In Pruritus, 363–77. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-33142-3_48.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Kolakowsky-Hayner, Stephanie A. "Antihistamines." In Encyclopedia of Clinical Neuropsychology, 203–4. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-0-387-79948-3_1628.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Antihistamine"

1

Hsieh, Hsiao-Yen, Yuan-Hung Wang, Cheng-Huang Shen, Shiu-Yi Chen, Michael W. Chan, and Cheng-Da Hsu. "Abstract 4561: The antihistamine cyproheptadine induces cell apoptosis through inhibition of β-catenin signaling pathways in urothelial carcinoma." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-4561.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Pillgram-Larsen, J., T. E. Ruud, J. O. Stadaas, and A. O. Aasen. "MULTITHERAPY PRETREATMENT IMPROVES HEMODYNAMIC FUNCTION IN EXPERIMENTAL ENDOTOXEMIA." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644892.

Full text

Abstract:

To evaluate the cardiopulmonary response to a newregimen of therapy in endotoxemia, ten pigs were infused with endotoxin 0.01 mg/kg over three hours. Five animals (treatment group) received therapy starting 30 min prior to endotoxin infusion consisting of repeated doses of protease inhibitor concentrates (C1esterase inhibitor 2000 IU, antithrombin III 500 IU,aprotinin 2 mill KIU), methylprednisolone 100 mg/kg, antihistamine(promethazin 1 mg/kg), a serotonin antagonist (ketanserine 2 mg/kg) and an opiate antagonist (naloxone 0.06 mg/kg). Five animals were untreated.Eight animals (control group) were anaesthetized and observed without endotoxin or treatment. The observation time was five hours. Two untreated animals receiving endotoxin died. Endotoxin caused a decrease in cardiac function with decreased left ventricular stroke work (LVSW). Endotoxin resulted in a marked increase in pulmonary vascular resistance (PVR) and oxygenation was impaired. With multiherapy cardiac output increased. Systemic vascular resistence was decreased in the treatment group while it increased steadily in the untreated group. LVSW was significantlybetter maintained in the treated animals. Pulmonary vascular resistence was unaltered in the treatment group. Pulmonary gas exchange was not different between the endotoxin infused groups. Endotoxin infusion caused no metabolic changes in this short time modelas oxygen consumption was not different between the three groups. Overall cardiopulmonary function was improved in treated animals compared to both untreated endotoxin infused animals and controls as mixed venous oxygen saturation was higher in the treatment group. Multitherapy has a protective effect on cardiopulmonary functions in experimental endotoxemia.

APA, Harvard, Vancouver, ISO, and other styles

3

YANAI, KAZUHIKO, TAKEO YOSHIKAWA, SHOZO FURUMOTO, NOBUYUKI OKAMURA, YOSHIHITO FUNAKI, and REN IWATA. "MOLECULAR IMAGING OF SEDATIVE PROPERTIES CAUSED BY ANTIHISTAMINES." In Proceedings of the Tohoku University Global Centre of Excellence Programme. IMPERIAL COLLEGE PRESS, 2012. http://dx.doi.org/10.1142/9781848169067_0028.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Li, Dailin, Chuanbo Dai, and Yangyang Jiang. "REVIEW ON THE PROGRESS IN THE SYNTHESIS OF ANTIHISTAMINES AND PROMETHAZINE." In International Conference on New Materials and Intelligent Manufacturing (ICNMIM). Volkson Press, 2018. http://dx.doi.org/10.26480/icnmim.01.2018.187.190.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Chanas-LaRue, Aaron P., James B. Johnston, and Spencer B. Gibson. "Abstract 3976: Antihistamines as synergists with targeted therapies in chronic lymphocytic leukemia." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-3976.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Fritz, Ildiko, Philippe Wagner, and Hakan L. Olsson. "Abstract 5582: H1-antihistamines desloratadine and loratadine show potential for cancer therapy." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-5582.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Olsson, Hakan L. "Abstract 5695: Use of certain antihistamines among breast cancer patients confers survival benefit." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-5695.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Troyanova-Wood, Maria A. "Assessing the effect of antihistamines in rodents with Raman and Brillouin spectroscopy (Conference Presentation)." In Optical Elastography and Tissue Biomechanics V, edited by Kirill V. Larin and David D. Sampson. SPIE, 2018. http://dx.doi.org/10.1117/12.2291364.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Poza, Jesus, Pere Caminal, Montserrat Vallverdu, Roberto Hornero, Sergio Romero, and Manuel J. Barbanoj. "Study of the EEG Changes during the Combined Ingestion of Alcohol and H1-antihistamines by using the Wavelet Transform." In 2007 29th Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE, 2007. http://dx.doi.org/10.1109/iembs.2007.4352213.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Eikje, Natalja Skrebova, and Seiji Arase. "Fiber optic LDF to monitor vascular dynamics of urticarial dermographism in pressure-tested patients before and after treatment with antihistamines." In Biomedical Optics (BiOS) 2008, edited by Nikiforos Kollias, Bernard Choi, Haishan Zeng, Reza S. Malek, Brian J. Wong, Justus F. R. Ilgner, Kenton W. Gregory, Guillermo J. Tearney, Henry Hirschberg, and Steen J. Madsen. SPIE, 2008. http://dx.doi.org/10.1117/12.763013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Antihistamine"

1

Schrot, John, John Thomas, and Karl F. Van Orden. Human Performance Following Antihistamine Administration. Fort Belvoir, VA: Defense Technical Information Center, March 1990. http://dx.doi.org/10.21236/ada233051.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Snyder, Harry S., and Valerie J. Rice. Complex Cognitive Performance and Antihistamine Use. Fort Belvoir, VA: Defense Technical Information Center, April 1990. http://dx.doi.org/10.21236/ada229120.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Schiflett, Samuel G. Antihistamine Drugs and Performance on C3 Tasks. Fort Belvoir, VA: Defense Technical Information Center, February 1992. http://dx.doi.org/10.21236/ada250762.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Nesthus, Thomas E., Samuel G. Schiflett, Douglas R. Eddy, and Jeffrey N. Whitmore. Comparative Effects of Antihistamines on Aircrew Performance of Simple and Complex Tasks Under Sustained Operations. Fort Belvoir, VA: Defense Technical Information Center, December 1991. http://dx.doi.org/10.21236/ada248752.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!